In human breast cancer therapy, unbalanced inhibition and activation of ER domains via high dose synthetic estrogen treatment led to controversial tumor responses and serious toxic complications via alterations in the expression of estrogen regulated genes. The gene discussed is ESR1; the disease is breast carcinoma.